North America Alpha-gal Syndrome Allergy Market Size & Outlook
Related Markets
North America alpha-gal syndrome allergy market highlights
- The North America alpha-gal syndrome allergy market generated a revenue of USD 65.6 million in 2025.
- The market is expected to grow at a CAGR of 7.8% from 2026 to 2033.
- In terms of segment, epinephrine was the largest revenue generating drug class in 2025.
- Corticosteroids is the most lucrative drug class segment registering the fastest growth during the forecast period.
- Country-wise, Mexico is expected to register the highest CAGR from 2026 to 2033.
North America data book summary
| Market revenue in 2025 | USD 65.6 million |
| Market revenue in 2033 | USD 119.3 million |
| Growth rate | 7.8% (CAGR from 2026 to 2033) |
| Largest segment | Epinephrine |
| Fastest growing segment | Corticosteroids |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Epinephrine, Antihistamines, Corticosteroids |
Other key industry trends
- In terms of revenue, North America region accounted for 84.0% of the global alpha-gal syndrome allergy market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- MEA is the fastest growing regional market and is projected to reach USD 1.5 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Alpha-Gal Syndrome Allergy Market Scope
Alpha-Gal Syndrome Allergy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Antares Pharma | View profile | 51-100 | Minneapolis, Minnesota, United States, North America | http://www.antarespharma.com/ |
| Teva Pharmaceutical Industries Ltd. | View profile | - | - | - |
| Adamis Pharmaceuticals | View profile | 11-50 | San Diego, California, United States, North America | http://www.adamispharmaceuticals.com |
| Alk-Abello A/S Class B | View profile | 2828 | Boge Alle 6-8, Horsholm, Denmark, DK-2970 | https://www.alk.net |
| Amneal Pharmaceuticals | View profile | 5001-10000 | Bridgewater, New Jersey, United States, North America | http://amneal.com/ |
| Bausch Health Companies Inc | View profile | 20270 | 2150 Saint Elzear Boulvard West, Laval, QC, Canada, H7L 4A8 | https://www.bauschhealth.com |
| Viatris Inc | View profile | 38000 | 1000 Mylan Boulevard, Canonsburg, PA, United States, 15317 | https://www.viatris.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
North America alpha-gal syndrome allergy market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to alpha-gal syndrome allergy market will help companies and investors design strategic landscapes.
Epinephrine was the largest segment with a revenue share of 61.13% in 2025. Horizon Databook has segmented the North America alpha-gal syndrome allergy market based on epinephrine, antihistamines, corticosteroids covering the revenue growth of each sub-segment from 2021 to 2033.
Reasons to subscribe to North America alpha-gal syndrome allergy market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America alpha-gal syndrome allergy market databook
-
Our clientele includes a mix of alpha-gal syndrome allergy market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America alpha-gal syndrome allergy market , including forecasts for subscribers. This continent databook contains high-level insights into North America alpha-gal syndrome allergy market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
North America alpha-gal syndrome allergy market size, by country, 2021-2033 (US$M)
North America Alpha-Gal Syndrome Allergy Market Outlook Share, 2025 & 2033 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
